JP2020533334A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533334A5 JP2020533334A5 JP2020514257A JP2020514257A JP2020533334A5 JP 2020533334 A5 JP2020533334 A5 JP 2020533334A5 JP 2020514257 A JP2020514257 A JP 2020514257A JP 2020514257 A JP2020514257 A JP 2020514257A JP 2020533334 A5 JP2020533334 A5 JP 2020533334A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai agent
- agent according
- nucleotides
- composition
- sense strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091030071 RNAI Proteins 0.000 claims description 106
- 239000003795 chemical substances by application Substances 0.000 claims description 106
- 230000009368 gene silencing by RNA Effects 0.000 claims description 106
- 125000003729 nucleotide group Chemical group 0.000 claims description 89
- 239000002773 nucleotide Substances 0.000 claims description 75
- 239000000203 mixture Substances 0.000 claims description 47
- 108091081021 Sense strand Proteins 0.000 claims description 46
- 230000000692 anti-sense effect Effects 0.000 claims description 36
- 239000003446 ligand Substances 0.000 claims description 32
- 230000008685 targeting Effects 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 16
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 14
- 101150001527 APOC3 gene Proteins 0.000 claims description 12
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 10
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 8
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 8
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 8
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 8
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 8
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 8
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 8
- FPUGCISOLXNPPC-IOSLPCCCSA-N cordysinin B Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-IOSLPCCCSA-N 0.000 claims description 8
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 229940029575 guanosine Drugs 0.000 claims description 8
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 8
- 229940045145 uridine Drugs 0.000 claims description 8
- 229930010555 Inosine Natural products 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229960003786 inosine Drugs 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 206010033645 Pancreatitis Diseases 0.000 claims description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 230000004060 metabolic process Effects 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- UUDVSZSQPFXQQM-GIWSHQQXSA-N (2r,3s,4r,5r)-2-(6-aminopurin-9-yl)-3-fluoro-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)F UUDVSZSQPFXQQM-GIWSHQQXSA-N 0.000 claims description 4
- FPUGCISOLXNPPC-UHFFFAOYSA-N 2'-O-Methyladenosine Natural products COC1C(O)C(CO)OC1N1C2=NC=NC(N)=C2N=C1 FPUGCISOLXNPPC-UHFFFAOYSA-N 0.000 claims description 4
- BXJSAMKIFDDLGI-UHFFFAOYSA-N 2-(dimethylamino)-N-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]benzamide Chemical compound COc1ccc(cc1S(=O)(=O)Nc1cccc(NCCNC(=O)c2ccccc2N(C)C)c1)-c1cccc(c1)C(=O)N(C)C BXJSAMKIFDDLGI-UHFFFAOYSA-N 0.000 claims description 4
- 102100030970 Apolipoprotein C-III Human genes 0.000 claims description 4
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 claims description 4
- 101000793223 Homo sapiens Apolipoprotein C-III Proteins 0.000 claims description 4
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 4
- 108010006523 asialoglycoprotein receptor Proteins 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- RHLMXWCISNJNDH-UHFFFAOYSA-N n-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]-3-methylbenzamide Chemical compound COC1=CC=C(C=2C=C(C=CC=2)C(=O)N(C)C)C=C1S(=O)(=O)NC(C=1)=CC=CC=1NCCNC(=O)C1=CC=CC(C)=C1 RHLMXWCISNJNDH-UHFFFAOYSA-N 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 4
- 206010014476 Elevated cholesterol Diseases 0.000 claims description 2
- 206010014486 Elevated triglycerides Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000002214 arabinonucleotide Substances 0.000 claims description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 125000001921 locked nucleotide group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023051640A JP2023073358A (ja) | 2017-09-11 | 2023-03-28 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556818P | 2017-09-11 | 2017-09-11 | |
| US62/556,818 | 2017-09-11 | ||
| US201862643927P | 2018-03-16 | 2018-03-16 | |
| US62/643,927 | 2018-03-16 | ||
| US201862720434P | 2018-08-21 | 2018-08-21 | |
| US62/720,434 | 2018-08-21 | ||
| PCT/US2018/050248 WO2019051402A1 (en) | 2017-09-11 | 2018-09-10 | RNA INTERFERENCE AGENTS AND COMPOSITIONS FOR INHIBITING THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023051640A Division JP2023073358A (ja) | 2017-09-11 | 2023-03-28 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533334A JP2020533334A (ja) | 2020-11-19 |
| JP2020533334A5 true JP2020533334A5 (enExample) | 2021-10-07 |
| JP7438103B2 JP7438103B2 (ja) | 2024-02-26 |
Family
ID=65630632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514257A Active JP7438103B2 (ja) | 2017-09-11 | 2018-09-10 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
| JP2023051640A Pending JP2023073358A (ja) | 2017-09-11 | 2023-03-28 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023051640A Pending JP2023073358A (ja) | 2017-09-11 | 2023-03-28 | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10597657B2 (enExample) |
| EP (1) | EP3681516A4 (enExample) |
| JP (2) | JP7438103B2 (enExample) |
| KR (2) | KR20240161202A (enExample) |
| CN (2) | CN111107853B (enExample) |
| AU (1) | AU2018329190B2 (enExample) |
| BR (1) | BR112020002413A2 (enExample) |
| CA (1) | CA3074303A1 (enExample) |
| CL (2) | CL2020000593A1 (enExample) |
| CO (1) | CO2020002586A2 (enExample) |
| CR (1) | CR20200108A (enExample) |
| EC (1) | ECSP20017905A (enExample) |
| IL (2) | IL273172B1 (enExample) |
| JO (1) | JOP20200054A1 (enExample) |
| MX (1) | MX2020002648A (enExample) |
| MY (1) | MY202025A (enExample) |
| PE (1) | PE20201283A1 (enExample) |
| PH (1) | PH12020500332A1 (enExample) |
| SG (1) | SG11201912178VA (enExample) |
| TN (1) | TN2020000039A1 (enExample) |
| TW (2) | TW202415389A (enExample) |
| UY (1) | UY37871A (enExample) |
| WO (1) | WO2019051402A1 (enExample) |
| ZA (1) | ZA202100806B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3221451A1 (en) | 2014-11-17 | 2017-09-27 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| CN109462981B (zh) * | 2016-09-02 | 2023-07-07 | 箭头药业股份有限公司 | 靶向配体 |
| LT3607069T (lt) | 2017-04-05 | 2023-01-10 | Silence Therapeutics Gmbh | Produktai ir kompozicijos |
| SG11201912178VA (en) * | 2017-09-11 | 2020-01-30 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
| JP7365052B2 (ja) | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| US11414661B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| MX2022001460A (es) * | 2019-08-05 | 2022-02-22 | Arrowhead Pharmaceuticals Inc | Metodos para el tratamiento de enfermedades y trastornos relacionados con apoc3. |
| AU2021224778A1 (en) * | 2020-02-18 | 2022-09-29 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof |
| CN114480382A (zh) * | 2020-11-12 | 2022-05-13 | 北京大学 | 用于抑制SURF4基因表达的RNAi试剂和组合物 |
| WO2022162155A1 (en) * | 2021-01-30 | 2022-08-04 | E-Therapeutics Plc | Nucleic acids containing abasic nucleotides |
| AU2022299514A1 (en) | 2021-06-24 | 2024-01-18 | Sirnaomics, Inc. | Products and compositions |
| CA3225015A1 (en) * | 2021-07-16 | 2023-01-19 | Zicai Liang | Nucleic acid, composition and conjugate containing same, and preparation method and use |
| JP2024537251A (ja) * | 2021-10-08 | 2024-10-10 | イー－セラピューティクス・ピーエルシー | 脱塩基ヌクレオシドを含有する核酸 |
| TW202330920A (zh) | 2021-12-01 | 2023-08-01 | 美商戴瑟納製藥股份有限公司 | 用於調節ａｐｏｃ３表現之組合物及方法 |
| WO2023138659A1 (zh) * | 2022-01-20 | 2023-07-27 | 上海拓界生物医药科技有限公司 | 一种dsRNA、其应用及制备方法 |
| TW202345865A (zh) * | 2022-01-24 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 抑制LPA(Apo(a))蛋白表達的組合物和方法 |
| CN116917477B (zh) | 2022-01-30 | 2024-04-09 | 大睿生物医药科技(上海)有限公司 | 含有n-乙酰半乳糖胺的靶向配体 |
| EP4541893A1 (en) | 2022-06-14 | 2025-04-23 | Rona Bioscience, Limited | Sirna molecule for regulating pcsk9 gene activity |
| AU2023299696A1 (en) * | 2022-06-27 | 2025-01-23 | Rona Bioscience, Limited | Sirna for inhibiting apolipoprotein c3 expression |
| EP4555088A1 (en) * | 2022-07-11 | 2025-05-21 | Sanegene Bio USA Inc. | Optimized 2'- modified ribose derivatives and methods of use |
| WO2024023254A1 (en) * | 2022-07-27 | 2024-02-01 | E-Therapeutics Plc | Nucleic acid compounds |
| US20250368992A1 (en) * | 2022-07-27 | 2025-12-04 | E-Therapeutics Plc | Nucleic acid compounds |
| AU2023313321A1 (en) * | 2022-07-27 | 2025-01-09 | E-Therapeutics Plc | Nucleic acid compounds |
| CN116814621B (zh) * | 2022-08-05 | 2025-09-09 | 厦门甘宝利生物医药有限公司 | 一种抑制apoc3基因表达的rna抑制剂及其应用 |
| WO2024032680A1 (zh) * | 2022-08-11 | 2024-02-15 | 益杰立科(上海)生物科技有限公司 | 一种表观编辑靶点的方法及用途 |
| WO2024165571A2 (en) * | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| AU2024218976A1 (en) * | 2023-02-06 | 2025-09-11 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2024188173A1 (zh) * | 2023-03-10 | 2024-09-19 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及其用途 |
| US20250243487A1 (en) | 2023-09-14 | 2025-07-31 | Ionis Pharmaceuticals, Inc. | Compounds and Methods for Reducing APOCIII Expression |
| WO2025087442A1 (zh) * | 2023-10-27 | 2025-05-01 | 北京安龙生物医药有限公司 | 靶向脂蛋白a的寡核苷酸及其用途 |
| WO2025125576A2 (en) * | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) * | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025184301A1 (en) * | 2024-02-29 | 2025-09-04 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for dual inhibition of expression of apolipoprotein c-iii (apoc3) and proprotein convertase subtilisin kexin 9 (pcsk9), compositions thereof, and methods of use |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| EP1159441B8 (en) | 1999-03-10 | 2008-10-29 | Marie Curie Cancer Care | Delivery of nucleic acids and proteins to cells |
| AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| EP1399189A1 (en) | 2001-06-11 | 2004-03-24 | Universite De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| AU2002324723B2 (en) | 2001-08-16 | 2007-10-25 | The Trustees Of The University Of Pennsylvania | Synthesis and use of reagents for improved DNA lipofection and/or slow release pro-drug and drug therapies |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| AU2003279004B2 (en) | 2002-09-28 | 2009-10-08 | Massachusetts Institute Of Technology | Influenza therapeutic |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| US20040204377A1 (en) | 2002-11-26 | 2004-10-14 | University Of Massachusetts | Delivery of siRNAs |
| US20040208921A1 (en) | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| US7598227B2 (en) * | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| SG190613A1 (en) | 2003-07-16 | 2013-06-28 | Protiva Biotherapeutics Inc | Lipid encapsulated interfering rna |
| CN1845993B (zh) | 2003-08-28 | 2010-06-23 | 诺瓦提斯公司 | 具有平端和3＇修饰的干扰rna双链体 |
| AU2005248147A1 (en) | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| US8101741B2 (en) | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| WO2007107162A2 (en) | 2006-03-23 | 2007-09-27 | Santaris Pharma A/S | Small internally segmented interfering rna |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| BRPI0715375A2 (pt) | 2006-08-18 | 2013-06-18 | Hoffmann La Roche | policonjugados para distribuiÇço in vivo de polinucleotÍdeos |
| BRPI0811170B8 (pt) | 2007-05-22 | 2021-05-25 | Arcturus Therapeutics Inc | oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila |
| US7615374B2 (en) | 2007-09-25 | 2009-11-10 | Wisconsin Alumni Research Foundation | Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions |
| CA2710713C (en) | 2007-12-27 | 2017-09-19 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering rna |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| WO2010083615A1 (en) * | 2009-01-26 | 2010-07-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein c-iii expression |
| EP3721943A1 (en) | 2009-12-23 | 2020-10-14 | Novartis AG | Lipids, lipid compositions and methods of using them |
| ES2562817T3 (es) | 2010-02-24 | 2016-03-08 | Arrowhead Research Corporation | Composiciones para el suministro dirigido de ARNip |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| MX344807B (es) | 2011-06-21 | 2017-01-09 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3). |
| MX2014001971A (es) | 2011-08-26 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(vinilester) para suministro de acido nucleico in vivo. |
| MX2014001965A (es) | 2012-04-18 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(acrilato) para suministro de acido nucleico in vivo. |
| EP3919620A1 (en) * | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| AU2014284152B2 (en) * | 2013-06-21 | 2020-01-23 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| WO2015051366A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
| WO2016011123A1 (en) * | 2014-07-16 | 2016-01-21 | Arrowhead Research Corporation | Organic compositions to treat apoc3-related diseases |
| EP3221451A1 (en) * | 2014-11-17 | 2017-09-27 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| US20160272970A1 (en) * | 2015-03-17 | 2016-09-22 | Arrowhead Madison Inc. | RNA Interference Agents |
| JOP20210043A1 (ar) * | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| CN109069529B (zh) | 2016-03-07 | 2021-08-20 | 箭头药业股份有限公司 | 用于治疗性化合物的靶向配体 |
| CN109462981B (zh) | 2016-09-02 | 2023-07-07 | 箭头药业股份有限公司 | 靶向配体 |
| WO2018223056A1 (en) * | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| SG11201912178VA (en) * | 2017-09-11 | 2020-01-30 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
-
2018
- 2018-09-10 SG SG11201912178VA patent/SG11201912178VA/en unknown
- 2018-09-10 US US16/126,740 patent/US10597657B2/en active Active
- 2018-09-10 CN CN201880059004.3A patent/CN111107853B/zh active Active
- 2018-09-10 EP EP18853495.2A patent/EP3681516A4/en active Pending
- 2018-09-10 MX MX2020002648A patent/MX2020002648A/es unknown
- 2018-09-10 CR CR20200108A patent/CR20200108A/es unknown
- 2018-09-10 PE PE2020000340A patent/PE20201283A1/es unknown
- 2018-09-10 WO PCT/US2018/050248 patent/WO2019051402A1/en not_active Ceased
- 2018-09-10 JO JOP/2020/0054A patent/JOP20200054A1/ar unknown
- 2018-09-10 CN CN202410900721.1A patent/CN118879696A/zh active Pending
- 2018-09-10 JP JP2020514257A patent/JP7438103B2/ja active Active
- 2018-09-10 CA CA3074303A patent/CA3074303A1/en active Pending
- 2018-09-10 KR KR1020247035695A patent/KR20240161202A/ko active Pending
- 2018-09-10 AU AU2018329190A patent/AU2018329190B2/en active Active
- 2018-09-10 TN TNP/2020/000039A patent/TN2020000039A1/en unknown
- 2018-09-10 KR KR1020207006708A patent/KR102723833B1/ko active Active
- 2018-09-10 BR BR112020002413-9A patent/BR112020002413A2/pt unknown
- 2018-09-10 MY MYPI2020001153A patent/MY202025A/en unknown
- 2018-09-11 UY UY0001037871A patent/UY37871A/es active IP Right Grant
- 2018-09-11 TW TW112125927A patent/TW202415389A/zh unknown
- 2018-09-11 TW TW107131910A patent/TWI811238B/zh active
-
2020
- 2020-01-31 US US16/778,188 patent/US11214801B2/en active Active
- 2020-02-13 PH PH12020500332A patent/PH12020500332A1/en unknown
- 2020-03-04 CO CONC2020/0002586A patent/CO2020002586A2/es unknown
- 2020-03-09 CL CL2020000593A patent/CL2020000593A1/es unknown
- 2020-03-09 IL IL273172A patent/IL273172B1/en unknown
- 2020-03-11 EC ECSENADI202017905A patent/ECSP20017905A/es unknown
-
2021
- 2021-02-05 ZA ZA2021/00806A patent/ZA202100806B/en unknown
- 2021-11-18 US US17/529,364 patent/US20220064646A1/en not_active Abandoned
-
2022
- 2022-12-22 US US18/145,218 patent/US12365899B2/en active Active
-
2023
- 2023-03-28 JP JP2023051640A patent/JP2023073358A/ja active Pending
-
2024
- 2024-11-13 CL CL2024003470A patent/CL2024003470A1/es unknown
-
2025
- 2025-10-26 IL IL324223A patent/IL324223A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533334A5 (enExample) | ||
| JP2020534268A5 (enExample) | ||
| TWI811238B (zh) | 用於抑制脂蛋白元C-III(APOC3)表現之RNAi試劑及組合物 | |
| TWI823866B (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| JP2018529732A5 (enExample) | ||
| JP6370860B2 (ja) | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 | |
| JP6472820B2 (ja) | アポリポタンパク質（ａ）発現を調節するための方法および組成物 | |
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| CN104994884B (zh) | 对脂蛋白脂肪酶缺乏(lpld)群体中的载脂蛋白c-iii(apociii)表达的调节 | |
| JP2022501040A (ja) | １７β−ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法 | |
| JP2017002061A (ja) | ヒトアポリポタンパク質ｂと相補的なアンチセンスオリゴヌクレオチドの投与 | |
| TWI881004B (zh) | 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合 | |
| JP2020526192A5 (enExample) | ||
| JPWO2020061177A5 (enExample) | ||
| JP2017510583A (ja) | 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー | |
| JP2023536999A (ja) | Ｂ型肝炎患者のオリゴヌクレオチド処置 | |
| JP2025061882A (ja) | Ａｐｏｃ３関連疾患および障害の処置のための方法 | |
| JP2020537653A5 (enExample) | ||
| JP2018511555A (ja) | リポジストロフィー集団におけるアポリポタンパク質Ｃ−ＩＩＩ（ＡｐｏＣＩＩＩ）発現の調節 | |
| JPWO2021167841A5 (enExample) | ||
| JP2025527670A (ja) | Ａｎｇｐｔｌ３関連疾患及び障害の治療方法 | |
| JPWO2021195467A5 (enExample) | ||
| EP4214316A2 (en) | Methods for the reduction of z-aat protein levels | |
| TH2001001206A (th) | RNAi เอเจนท์และองค์ประกอบสำหรับการยับยั้งการแสดงออกของอะโปลิโพโปรตีน C-II (APOC3) | |
| RU2851259C1 (ru) | Способы снижения уровней белка z-aat |